Seroatlas · Human Serome Atlas

TREML2

Trem-like transcript 2 protein

Also known as: C6orf76, dJ238O23.1, FLJ13693, TLT2, TRML2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q5T2D2
Gene: TREML2
Ensembl: ENSG00000112195
Chromosome: 6
Canonical length: 321 aa
Protein class: Plasma proteins, Predicted membrane proteins

OverviewNCBI Gene

TREML2 is located in a gene cluster on chromosome 6 with the single Ig variable (IgV) domain activating receptors TREM1 (MIM 605085) and TREM2 (MIM 605086), but it has distinct structural and functional properties (Allcock et al., 2003 [PubMed 12645956]).[supplied by OMIM, Mar 2008]

Canonical amino-acid sequenceUniProt

321 residues, UniProt reviewed canonical sequence.

>Q5T2D2|TREML2
     1  MAPAFLLLLL LWPQGCVSGP SADSVYTKVR LLEGETLSVQ CSYKGYKNRV EGKVWCKIRK
    61  KKCEPGFARV WVKGPRYLLQ DDAQAKVVNI TMVALKLQDS GRYWCMRNTS GILYPLMGFQ
   121  LDVSPAPQTE RNIPFTHLDN ILKSGTVTTG QAPTSGPDAP FTTGVMVFTP GLITLPRLLA
   181  STRPASKTGY SFTATSTTSQ GPRRTMGSQT VTASPSNARD SSAGPESIST KSGDLSTRSP
   241  TTGLCLTSRS LLNRLPSMPS IRHQDVYSTV LGVVLTLLVL MLIMVYGFWK KRHMASYSMC
   301  SDPSTRDPPG RPEPYVEVYL I

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TREML2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.56
Highest tissue expression: 14 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 14 nTPM
lymph node: 9 nTPM
tonsil: 7 nTPM
spleen: 6.6 nTPM
thymus: 6.4 nTPM
appendix: 6 nTPM

Single-cell type

neutrophils: 75 nCPM
late spermatids: 60 nCPM
early spermatids: 29 nCPM
syncytiotrophoblasts: 22 nCPM
megakaryocytes: 19 nCPM
pdcs: 9.5 nCPM

Immune cell

neutrophil: 33 nTPM
naive B-cell: 23 nTPM
eosinophil: 13 nTPM
plasmacytoid DC: 9.3 nTPM
memory B-cell: 6 nTPM
basophil: 2.6 nTPM

Brain region

hypothalamus: 2.4 nTPM
cerebral cortex: 2.2 nTPM
basal ganglia: 1.8 nTPM
cerebellum: 1.8 nTPM
pons: 1.8 nTPM
hippocampal formation: 1.7 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.72
gnomAD pLI: 0
gnomAD missense Z: 0.29
DepMap mean gene effect: -0.07
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

T cell activation

Molecular functions

signaling receptor activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TREML2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

CD276

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TREML2 as an antibody target. Whether an autoantibody or antibody against TREML2 could matter depends on whether native TREML2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TREML2 is annotated at the cell surface, where native TREML2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TREML2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...